Back

Randomized, double-blind, placebo-controlled, efficacy and safety study of etripamil self-administration for the termination of episodes of paroxysmal supraventricular tachycardia in chinese patients

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Supraventricular tachycardia Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Nan Li

Beijing Anzhen Hospital, Beijing (China)

6 More presentations in this session

Presentation thumbnail
The impact of predictors used in differentiation between paroxysmal supraventricular tachycardia and ischemic heart disease in young patients with elevated high-sensitive troponin
Doctor A. Ceviker (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
A large footprint catheter toggling between pulsed field and radiofrequency energy: first clinical experience for inappropriate sinus node tachycardia ablation
Professor C. de Asmundis (Brussels, BE)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes and efficacy of focal atrial tachycardia originating from the aortic root compared to right and left atrial FAT
Mr M. Truhan (DE)
Abstract Slides Video
Presentation thumbnail
Zero X ray approach for the ablation of Supraventricular Tachycardia performed exclusively by wOmen OPerators: The STOOP Multicenter Registry
Doctor S. Poggi (Napoli, IT)
Abstract Slides Video
Presentation thumbnail
Prevalence of stroke and mortality in patients with atrial tachycardia: insights from the SATELLITE Study Group
Doctor A. Kahle (Duesseldorf, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Supraventricular tachycardia

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Quality of life measures with etripamil self-administration for acute episodes of paroxysmal supraventricular tachycardia in a medically unsupervised setting: patient-reported outcomes from NODE-303
thumbnail
Congress Presentation
Etripamil - a multichannel modulator to suppress atrial fibrillation
thumbnail
Congress Presentation
Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources